Dr. John Cush RheumNow
1 year 3 months ago
Deucravacitinib's Place in the PsA Treatment Algorithm?
Dr. Eric Ruderman offers his perspective on where deucravacitinib will fit in the treatment algorithm and trials presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/6Ozrvr5IMt https://t.co/w7FJs4wir9
Dr. John Cush RheumNow
1 year 3 months ago
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/F8WzGohCj8 https://t.co/FguBLrmPzZ
Dr. John Cush RheumNow
1 year 3 months ago
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow
1 year 3 months ago
Pregnancy outcomes in autoinflammatory disease
To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual https://t.co/oQ7A2bnDmO
Dr. John Cush RheumNow
1 year 3 months ago
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk
- Chikungunya
- Dengue
- Zika
- West-Nile Virus
@RheumNow #EULAR2025 @bella_mehta https://t.co/CCOYqTjaXE
Dr. John Cush RheumNow
1 year 3 months ago
From Domains to Decisions: Personalizing PsA Care with Data
At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; https://t.co/tzgE7U4eSj
Dr. John Cush RheumNow
1 year 3 months ago
New ideas in gout management
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX
Dr. John Cush RheumNow
1 year 3 months ago
Reviewing Three Osteoarthritis Studies
Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR
Dr. John Cush RheumNow
1 year 3 months ago
Which CAR T Cell is Mighty?
Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/MkRoqlvdub https://t.co/R0dtllmo7Q
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we
During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR 2025, data from Phase 2 RCT of efgartigimod, an FcRn-inhibitor were presented in autoantibodies positive, moderate to severe active SjD. In addition to SjD
